Renova Therapeutics
Developer of gene therapies for congestive heart failure and type 2 diabetes. The company’s lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene – urocortin 2 – using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute…
Funding snapshot
About
Developer of gene therapies for congestive heart failure and type 2 diabetes. The company’s lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene – urocortin 2 – using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute decompensated heart failure. Founded in 2009, headquartered in San Diego, United States. The company has raised $7.7M at the Series C stage backed by investors including NIH, HHS, K3, BioBrit. Operating in Life Sciences > Genomics, Life Sciences > Gene Therapy.
Business model
Diabetes > Drugs,
Cardiac and Vascular Disorders > Drugs > Heart Failure,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.